Document is current
Any future updates will be listed below
-
Authors
Shaw, Timothy I. https://orcid.org/0000-0002-9316-1924
Pounds, Stanley https://orcid.org/0000-0002-9167-2114
Cao, Xueyuan https://orcid.org/0000-0002-4396-7460
Ma, Jing
Palacios, Gustavo
Mason, John
Perkins, Sherrie
Wu, Gang https://orcid.org/0000-0002-1678-5864
Fan, Yiping
Wang, Jian
Zhou, Xin https://orcid.org/0000-0003-3979-8200
Obermayer, Alyssa https://orcid.org/0000-0002-7333-973X
Kinney, Marsha C.
Kraveka, Jacqueline
Gross, Thomas
Sandlund, John
Zhang, Jinghui https://orcid.org/0000-0003-3350-9682
Mullighan, Charles https://orcid.org/0000-0002-1871-1850
Lim, Megan S.
Leventaki, Vasiliki https://orcid.org/0000-0003-1145-3550
- License Information
-
More Information
Article History
Received: 21 March 2024
Revised: 30 October 2024
Accepted: 6 November 2024
First Online: 26 November 2024
Competing interests
: TIS reports a patent for EBD CAR pending. CGM reports personal fees from Illumina during the conduct of the study, as well as grants from Pfizer and AbbVie, and other support from Amgen outside the submitted work. No disclosures were reported by the other authors.
: This study was conducted in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects. Informed written consent was obtained from all patients and/or their legal guardians before enrollment in the study. The St. Jude Children’s Research Hospital Institutional Review Board approved the use of excess diagnostic material and data for this study (XPD14-018). All methods were performed in accordance with the relevant guidelines and regulations.
